Y Intercept Hong Kong Ltd Purchases Shares of 52,509 Phreesia, Inc. $PHR

Y Intercept Hong Kong Ltd acquired a new position in shares of Phreesia, Inc. (NYSE:PHR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 52,509 shares of the company’s stock, valued at approximately $1,235,000. Y Intercept Hong Kong Ltd owned 0.09% of Phreesia as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Asset Management One Co. Ltd. acquired a new position in Phreesia in the third quarter worth about $45,000. Farther Finance Advisors LLC grew its stake in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after purchasing an additional 3,000 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Phreesia in the 3rd quarter worth approximately $83,000. Tower Research Capital LLC TRC raised its holdings in shares of Phreesia by 332.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock worth $160,000 after buying an additional 4,313 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Phreesia during the 2nd quarter worth approximately $246,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Stock Down 3.9%

Shares of NYSE PHR opened at $13.41 on Friday. The firm’s 50-day simple moving average is $17.18 and its 200 day simple moving average is $22.40. The company has a market cap of $808.49 million, a price-to-earnings ratio of -134.09 and a beta of 0.61. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia, Inc. has a 12-month low of $13.40 and a 12-month high of $32.76.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The firm had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. During the same quarter last year, the company posted ($0.25) EPS. The company’s quarterly revenue was up 12.7% compared to the same quarter last year. On average, research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Transactions at Phreesia

In other news, insider David Linetsky sold 6,106 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the sale, the insider owned 231,723 shares in the company, valued at $3,941,608.23. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $44,260.02. Following the completion of the transaction, the senior vice president owned 160,238 shares in the company, valued at approximately $2,725,648.38. This represents a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,766 shares of company stock worth $1,013,817 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. BMO Capital Markets assumed coverage on Phreesia in a research report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price target on the stock. Wall Street Zen upgraded shares of Phreesia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Barclays lowered their target price on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Needham & Company LLC reissued a “buy” rating and set a $35.00 price target on shares of Phreesia in a report on Monday, December 8th. Finally, DA Davidson reduced their price target on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Seventeen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.76.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.